RGD Reference Report - An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Authors: Le, QT  Chen, E  Salim, A  Cao, H  Kong, CS  Whyte, R  Donington, J  Cannon, W  Wakelee, H  Tibshirani, R  Mitchell, JD  Richardson, D  O'Byrne, KJ  Koong, AC  Giaccia, AJ 
Citation: Le QT, etal., Clin Cancer Res. 2006 Mar 1;12(5):1507-14.
RGD ID: 1581361
Pubmed: PMID:16533775   (View Abstract at PubMed)
DOI: DOI:10.1158/1078-0432.CCR-05-2049   (Journal Full-text)

BACKGROUND: To directly assess tumor oxygenation in resectable non-small cell lung cancers (NSCLC) and to correlate tumor pO2 and the selected gene and protein expression to treatment outcomes. METHODS: Twenty patients with resectable NSCLC were enrolled. Intraoperative measurements of normal lung and tumor pO2 were done with the Eppendorf polarographic electrode. All patients had plasma osteopontin measurements by ELISA. Carbonic anhydrase-IX (CA IX) staining of tumor sections was done in the majority of patients (n = 16), as was gene expression profiling (n = 12) using cDNA microarrays. Tumor pO2 was correlated with CA IX staining, osteopontin levels, and treatment outcomes. RESULTS: The median tumor pO2 ranged from 0.7 to 46 mm Hg (median, 16.6) and was lower than normal lung pO2 in all but one patient. Because both variables were affected by the completeness of lung deflation during measurement, we used the ratio of tumor/normal lung (T/L) pO2 as a reflection of tumor oxygenation. The median T/L pO2 was 0.13. T/L pO2 correlated significantly with plasma osteopontin levels (r = 0.53, P = 0.02) and CA IX expression (P = 0.006). Gene expression profiling showed that high CD44 expression was a predictor for relapse, which was confirmed by tissue staining of CD44 variant 6 protein. Other variables associated with the risk of relapse were T stage (P = 0.02), T/L pO2 (P = 0.04), and osteopontin levels (P = 0.001). CONCLUSIONS: Tumor hypoxia exists in resectable NSCLC and is associated with elevated expression of osteopontin and CA IX. Tumor hypoxia and elevated osteopontin levels and CD44 expression correlated with poor prognosis. A larger study is needed to confirm the prognostic significance of these factors.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
lung non-small cell carcinoma  IDA 1581361 RGD 
lung non-small cell carcinoma  ISOSPP1 (Homo sapiens)1581361; 1581361 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Spp1  (secreted phosphoprotein 1)

Genes (Mus musculus)
Spp1  (secreted phosphoprotein 1)

Genes (Homo sapiens)
SPP1  (secreted phosphoprotein 1)


Additional Information